Core Viewpoint - Hims & Hers Health has experienced a significant stock decline of 47.96% over the past month, yet analysts maintain a positive outlook with an average price target of $29.96, suggesting an 84% upside potential from current levels [2][7]. Regulatory Impact - The stock collapse was triggered by an FDA crackdown on Hims' compounded weight-loss drugs, which raised concerns over quality and safety, leading to a 14.1% drop in after-hours trading on February 7 [8]. - A subsequent patent lawsuit from Novo Nordisk forced Hims to cancel its Wegovy alternative, further exacerbating the stock's decline [8][9]. Financial Performance - Hims reported Q3 revenue of $599 million, reflecting a 49% year-over-year growth, with a robust subscriber base of 2.5 million, marking a 21% increase year-over-year [4][11]. - The company generated $148.7 million in operating cash flow during Q3, indicating strong financial health [4]. Analyst Sentiment - Despite the recent challenges, Wall Street analysts remain optimistic, with 1 analyst rating it as Strong Buy, 2 as Buy, and 10 as Hold, while only 2 analysts have Sell ratings [10]. - The bullish outlook is based on Hims' potential to diversify beyond weight loss and continue strong subscriber growth and cash generation [10]. Future Outlook - The CEO of Hims, Andrew Dudum, expressed confidence in achieving long-term targets of over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 [12].